In the News
Press Releases
Alzheon Publishes New Analyses Showing Clinical Benefit of Tramiprosate in APOE4/4 Homozygous Patients at the Mild Stage of Alzheimer’s Disease; Clinical Effects Suggest Disease Modification Potential and Align with Preclinical Effects on Beta Amyloid Oligomer Formation
Analyses from Phase 3 Studies Published in The Journal of the Prevention of Alzheimer’s Disease Show Strongest Clinical Benefit of Tramiprosate in APOE4/4 Homozygous Patients with Mild AD [...]
Alzheon Scientists Discover Novel Therapeutic Mechanism of Inhibition of Formation of Toxic Beta Amyloid Oligomers, Key Driver of Alzheimer’s Disease Pathogenesis
Published Data Shows that Novel ‘Enveloping’ Mechanism of Tramiprosate Modulates Misfolding of Aß42 Amyloid and Prevents Oligomer Formation Early in Amyloid Aggregation Cascade Pharmacokinetic Analyses Confirm Tramiprosate [...]
Alzheon Publishes New Analyses from Phase 3 Studies Showing Clinical Benefit of Tramiprosate in Alzheimer’s Patients Who Are Carriers of APOE4, the Major Genetic Risk Factor in up to 65 Percent of Alzheimer’s Patients
Data published in The Journal of the Prevention of Alzheimer’s Disease is the first report to associate efficacy of an amyloid-targeted drug with the number of [...]
Alzheon Presents Positive Results of ALZ-801 Clinical Studies that Lead to Advancement to Pivotal Phase 3 Study in Alzheimer’s Patients with APOE4/4 Homozygous Genotype
Pharmacokinetic and Safety Data from Phase 1b Studies with ALZ-801, an Optimized Prodrug of Tramiprosate, Presented at the Alzheimer's Association International Conference FRAMINGHAM, Mass., July 25, [...]
Alzheon Announces Efficacy Analyses of Prior Tramiprosate Phase 3 Studies Showing Clinically Meaningful Benefits on Key Clinical Endpoints in Alzheimer’s Disease Patients with APOE4 Genotype
Results Support Advancement of ALZ‐801 into Pivotal Clinical Studies in APOE4/4 Homozygous Subjects with Mild to Moderate Alzheimer’s Disease Data Presented at the 14th Annual International [...]
Alzheon Announces Presentations at Two Upcoming Investor Conferences
FRAMINGHAM, Mass., November 12, 2015 – Alzheon, Inc., a clinical-stage biopharmaceutical company focused on developing new medicines for patients suffering from Alzheimer’s disease and other neurological and psychiatric disorders, [...]